Advancing together and moving forward: Combination gene and cellular immunotherapies

Priceman, Saul J.; Cheema, Waseem; Adusumilli, Prasad S.

doi:10.1016/j.omto.2022.05.005

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basic concept of this investigation was to identify biomarkers and druggable targets from a large panel of oxidative stress response genes. In the past few years, a paradigm shift took place in cancer therapy from cytotoxic to targeted therapy [ 26 , 27 , 28 , 29 ]. This concept can be applied to cancer prevention as well as to cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining

Özenver

Efferth

2023

Pharmaceutics

View full text Add to dashboard Cite

(1) Background: Oxidative stress is crucial in carcinogenesis and the response of tumors to treatment. Antioxidant genes are important determinants of resistance to chemotherapy and radiotherapy. We hypothesized that genes involved in the oxidative stress response may be valuable as prognostic biomarkers for the survival of cancer patients and as druggable targets. (2) Methods: We mined the KM Plotter and TCGA Timer2.0 Cistrome databases and investigated 205 antioxidant genes in 21 different tumor types within the context of this investigation. (3) Results: Of 4347 calculations with Kaplan–Meier statistics, 84 revealed statistically significant correlations between high gene expression and worse overall survival (p < 0.05; false discovery rate ≤ 5%). The tumor types for which antioxidant gene expression was most frequently correlated with worse overall survival were renal clear cell carcinoma, renal papillary cell carcinoma, and hepatocellular carcinoma. Seventeen genes were clearly overexpressed in tumors compared to their corresponding normal tissues (p < 0.001), possibly qualifying them as druggable targets (i.e., ALOX5, ALOX5AP, EPHX4, G6PD, GLRX3, GSS, PDIA4, PDIA6, PRDX1, SELENOH, SELENON, STIP1, TXNDC9, TXNDC12, TXNL1, TXNL4A, and TXNRD1). (4) Conclusions: We concluded that a sub-set of antioxidant genes might serve as prognostic biomarkers for overall survival and as druggable targets. Renal and liver tumors may be the most suitable entities for this approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining

Özenver

Efferth

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…151 CAR-T therapies face numerous challenges, particularly the immunologically "cold" tumor microenvironment and tumor heterogeneity of prostate cancer. 152 Rational combination therapies such as coadministration of CAR-T with PD-L1 blockade, 153 BiTEs, effector editing via CRISPR/Cas9, or oncolytic viruses are all underway to address issues with T cell trafficking, persistence, and activity, to augment efficacy. 152 Finally, the optimal timing to treat prostate cancer with cellular therapies remains an open question in the context of immune exhaustion, heterogeneous disease, and numerous metastatic sites in late-stage disease.…”

Section: T Cell Engagers and Chimeric Antigen Receptor (Car)-t Cell T...mentioning

confidence: 99%

“…The lymphodepleting chemotherapy required before CAR‐T administration was demonstrated to have additional effects on the prostate tumor microenvironment including increases in CAR‐T infiltration, CD8/Treg ratio, M1/M2 ratio, and an overall increased pro‐inflammatory signal 151 . CAR‐T therapies face numerous challenges, particularly the immunologically “cold” tumor microenvironment and tumor heterogeneity of prostate cancer 152 . Rational combination therapies such as coadministration of CAR‐T with PD‐L1 blockade, 153 BiTEs, effector editing via CRISPR/Cas9, or oncolytic viruses are all underway to address issues with T cell trafficking, persistence, and activity, to augment efficacy 152 .…”

Section: Advancing Immunotherapy For the Treatment Of Prostate Cancermentioning

confidence: 99%

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira,

Kamran,

Jamaspishvili

et al. 2024

The Prostate

View full text Add to dashboard Cite

IntroductionThe 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.MethodsThe 2023 marked the 10th Annual CHPCA Meeting, a discussion‐oriented scientific think‐tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.ResultsThe central topic areas covered at the meeting included: targeting transcription factor neo‐enhancesomes in cancer, AR as a pro‐differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence‐driven precision medicine.DiscussionThis article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.

show abstract

Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1

Quach

Hou

Bellis

et al. 2022

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Advancing together and moving forward: Combination gene and cellular immunotherapies

Cited by 3 publications

References 24 publications

Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining

Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1

Contact Info

Product

Resources

About